替吉奥联合沙利度胺二线治疗晚期胰腺癌的疗效观察  

Effect of second line treatment with S-1 and thalidomide in patients with advanced pancreatic cancer

作　　者：赵瑾[1] 李兴德[2] 孙广玉[3] 周军[4] 史英[1] 李永生[1] 高敬华[1] 

机构地区：[1]沧州市中心医院肿瘤内科,河北沧州061000 [2]沧州市中心医院放疗科,河北沧州061000 [3]山东省滨州市人民医院肿瘤一科 [4]山东大学齐鲁医院介入科

出　　处：《中华胰腺病杂志》2015年第4期229-232,共4页Chinese Journal of Pancreatology

摘　　要：目的观察替吉奥联合沙利度胺二线治疗晚期胰腺癌的临床疗效，探讨沙利度胺在胰腺癌治疗中的疗效和安全性。方法收集2010年7月至2012年10月沧州市中心医院肿瘤内科收治的60例胰腺癌患者，采用随机、平行对照的方法分为单药组和联合组，分别给予单药替吉奥或替吉奥联合沙利度胺治疗，评价两组患者的疗效和不良反应。结果单药组和联合组患者的疾病控制率分别为36．7％和46．7％，差异无统计学意义（P=0．31）；两组无进展生存期分别为2．9个月和3．3个月，联合组显著长于单药组，差异有统计学意义（P〈0．05）；联合组的Kamofsky评分、疼痛、睡眠和体重状况改善率分别为63．3％、46．7％、66．7％和53．3％，均显著优于单药组的30．0％、13．3％、30．0％和20．0％，差异有统计学意义（P值均〈0．05）。两组患者化疗的不良反应主要为恶心、呕吐、疲劳和嗜睡，多为Ⅰ-Ⅱ度。结论替吉奥联合沙利度胺二线治疗胰腺癌能够延长患者的无进展生存期，且安全性好，能提高患者生活质量。Objective To investigates the efficacy and tolerability of second line treatment with S-1 plus thalidomide in patients with advanced pancreatic cancer. Methods Sixty patients hospitalized in Department of Oncology of Cangzhou Central Hospital from July 2010 to October 2012 were included in this study. All the patients were diagnosed as having pancreatic carcinoma. The patients were randomly divided into two groups, one group was treated with S-1 alone, and the other group was treated with S-1 plus thalidomide. Then the efficacy and toxicity of two groups was evaluated. Results The disease control rates were 36.7% and 46.7% in the S-1 alone group and the S-1 plus thalidomide group, and the difference between the two groups was not statistically significant （P = 0.31 ）. The progression free survival （PFS）was 2.9 months and 3.3 months, and the difference between the two groups was statistically significant （P 〈 0.05）, the Karnofsky score, pain, sleep and weight improvement rate was 63.3%, 46.7% , 66.7% and 53.3% in combination group, which were significantly better than those in control group （30.0% , 13.3% , 30.0% and 20.0% ） , and the difference between the two groups was statistically significant （P 〈 0.05 ）. The major adverse events were nausea, vomiting, fatigue and drowsiness, mainly of grades I -- II. Conclusions S-1 plus thalidomide as second line treatment of pancreatic cancer can prolong the PSF of patients with advanced pancreatic cancer with excellent safety, and patients＇ quality of life is also improved.

关 键 词：胰腺肿瘤 药物疗法 疗效比较研究 替吉奥 沙利度胺 

分 类 号：R735.9[医药卫生—肿瘤]